2014
DOI: 10.1016/j.jacc.2014.01.063
|View full text |Cite
|
Sign up to set email alerts
|

Lipoprotein(a) Levels in Familial Hypercholesterolemia

Abstract: Lp(a) is an independent predictor of CVD in men and women with FH. The risk of CVD is higher in those patients with an Lp(a) level >50 mg/dl and carrying a receptor-negative mutation in the LDLR gene compared with other less severe mutations.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
65
0
4

Year Published

2015
2015
2021
2021

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 303 publications
(91 citation statements)
references
References 24 publications
4
65
0
4
Order By: Relevance
“…11,69 Traditional cardiovascular risk factors and lipoprotein(a) levels adversely affect the natural history of FH and CAD rates. 61,[70][71][72][73][74] Levels of lipoprotein(a) are inherited as a codominant trait. Lipoprotein(a) is established as a cardiovascular risk factor in the FH and non-FH population when levels exceed 50 mg/dL (75 nmol/L) with isoform-independent assays.…”
Section: Adulthoodmentioning
confidence: 99%
“…11,69 Traditional cardiovascular risk factors and lipoprotein(a) levels adversely affect the natural history of FH and CAD rates. 61,[70][71][72][73][74] Levels of lipoprotein(a) are inherited as a codominant trait. Lipoprotein(a) is established as a cardiovascular risk factor in the FH and non-FH population when levels exceed 50 mg/dL (75 nmol/L) with isoform-independent assays.…”
Section: Adulthoodmentioning
confidence: 99%
“…5 Although the type of mutation is probably the most influent variable in the clinical expression of ASCVD in FH, there are other genetic, environmental, and metabolic risk factors that might play a significant role in modulating the atherosclerotic burden in these individuals but the interaction among these risk factors and LDL-C levels in both FH subjects and their unaffected relatives is not well understood. [6][7][8] Published estimates of the magnitude of ASCVD risk are highly variable. Furthermore, many reports on this topic were conducted before the introduction of statins as a standard treatment.…”
mentioning
confidence: 99%
“…Remiantis tyrimais, klasikiniai rizikos veiksniai dažniau buvo nustatyti tarp mirusių jauno amžiaus ŠH asmenų nei tarp mirusių vyresnio amžiaus [24]. Įvairių tyrimų metu įrodyta, kad padidėjusi lipoproteino (a) (Lp(a)) koncentracija yra susijusi su didesne ŠKL rizika tiek bendroje populiacijoje, tiek tarp sergančių ŠH [19,25]. ŠH atveju paprastai nustatoma padidėjusi Lp(a) koncentracija.…”
Section: Rizikaunclassified
“…Lp(a) koncentracijos kraujyje koregavimas keičiant gyvenseną ar taikant gydymą statinais nėra efetyvus. Siekiant Lp(a) koncentracijos kraujyje < 0,5 g/l, taikytina mažo tankio lipoproteinų aferezė [25].…”
Section: Rizikaunclassified